ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingJulie McCormack discusses her annual AITI Golf Outing and why she continues to be a Celiac Disease Foundation top Team Gluten-Free fundraiser.
Continue ReadingOften, when a patient is following a long-term gluten-free diet with good compliance, micronutrient deficiencies cannot be detected. This review - published in the scientific journal Medicina - evaluates the most recent literature on micronutrient deficiencies in patients following a long-term gluten-free diet in order to provide dietary supplementation advice. The study concludes that in patients with micronutrient deficiencies caused by celiac disease, vitamin supplements may be necessary.
Continue ReadingThe Celiac Disease Foundation is proud to announce that Bradley J. Herrema, Secretary of the Foundation’s Board of Directors, has been selected for recognition as one the 2020 Best Lawyers in America.
Continue ReadingA study published by the Journal of the American Medical Association (JAMA) concluded that higher gluten intake during the first 5 years of life is correlated with an increased risk of celiac disease among children who possess the HLA genes associated with celiac disease. The study was conducted in research centers in the United States, Finland, Germany, and Sweden.
Continue ReadingThe Celiac Disease Foundation was proud to be an endorsement partner of the 2019 James W. Freston Conference – Food at the Intersection of Gut Health and Disease to educate…
Continue ReadingOn August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001…
Continue ReadingTeam Gluten-Free runners will run the 26.2 miles in the 2019 TCS NYC Marathon to accelerate research for the three million Americans affected by celiac disease.
Continue ReadingWritten by Francisco Leon, MD, PhD, Chief Scientific Officer, Co-Founder, Provention Bio Current guidelines recommend routine follow-up for celiac disease with dietary interviews and celiac blood tests, though these methods…
Continue ReadingBrett is committed to inspiring people with celiac disease to travel the world and explore the infinite opportunities to live gluten-free anywhere. Whether it is a short weekend visit, or…
Continue Reading